
Global Network
Our strength lies in a global community united by a shared purpose.
Across continents, patient organisations and advocates share one goal: to accelerate research and help bring effective therapies to everyone affected by SLC6A1-related neurodevelopmental disorder (SLC6A1-NDD).

Amber Freed
Founder and CEO
SLC6A1 Connect
Amber Freed is the founder and CEO of SLC6A1 CONNECT, the American and global patient association that has had, and continues to have, a significant impact on advancing SLC6A1 research.
Amber is the mother of twins, Riley and Maxwell. Maxwell was diagnosed with the SLC6A1 mutation at 18 months of age. With extraordinary determination, Amber turned the pain of her son’s diagnosis into purpose and has since been tirelessly dedicated to the SLC6A1 cause.
Our community is profoundly grateful to Amber and to everyone who supports her daily for their incredible commitment.
For more information about the American association, visit:

Lindsay Randall
President
SLC6A1 Europe
The foundation of the SLC6A1 EUROPE Alliance was largely made possible thanks to Lindsay Randall, founder and CEO of SLC6A1 CONNECT UK and mother of Arthur and Eden, both affected by SLC6A1 neurodevelopmental disorder.
Thanks to her vision, determination, and energy, she has played a key role in establishing our Alliance, which continues to grow by bringing together families, doctors, and researchers across Europe.
We are deeply grateful to Lindsay for her remarkable contribution and unwavering commitment.

Stuart Place
Co-Founder and Director
SLC6A1 Kids, Australia
The establishment of SLC6A1 Kids has been driven by the dedication and leadership of Stuart Place, co-founder and director of the Australian charity.
As the father of Will, diagnosed with SLC6A1 neurodevelopmental disorder in 2021, Stuart transformed his family’s experience into a mission to accelerate research for all children affected by the disorder.
Through his vision, Stuart has helped build one of the world’s most important patient-led initiatives focused on advancing precision medicine for SLC6A1.
We are sincerely grateful to Stuart for his invaluable contribution to the global SLC6A1 community.
For more information about the Australian association, visit: